High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia.

ABSTRACT:

Background

Acute myeloid leukemia (AML) is a heterogeneous disease of the hematopoietic system, for which identification of novel molecular markers is potentially important for clinical prognosis and is an urgent need for treatment optimization.

Methods

We selected C-type lectin domain family 11, member A (CLEC11A) for study via several public databases, comparing expression among a variety of tumors and normal samples as well as different organs and tissues. To investigated the relationship between CLEC11A expression and clinical characteristics, we derived an AML cohort from The Cancer Genome Atlas (TCGA); we also investigated the Bloodspot and HemaExplorer databases. The Kaplan-Meier method and log-rank test were used to evaluate the associations between CLEC11A mR

SUBMITTER: Yin C 

PROVIDER: S-EPMC7966831 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature